(:ZGNX)

Mar 07, 2022 11:00 am ET
UCB Completes Acquisition of Zogenix, Inc.
BRUSSELS, Belgium and ATLANTA, March 7, 2022 /PRNewswire/ -- UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up to approximately US $1.9 billion / €1.7 billion*.
Mar 04, 2022 08:00 am ET
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company’s research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome...
Feb 28, 2022 08:00 am ET
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2021. “The year 2021...
Feb 15, 2022 08:00 am ET
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the company is sponsoring a new no-cost genetic testing program, the United Mitochondrial Disease Foundation (UMDF) Pilot Genetic...
Feb 14, 2022 08:30 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ECOL, EYES, ZGNX, FLMN
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 03, 2022 06:11 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates APR, ZGNX, TSC, CCMP
NEW YORK, Feb. 3, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 31, 2022 12:18 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates APR, ZGNX, CRHC, DNAA
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Apria, Inc. (NASDAQ: APR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jan 27, 2022 11:12 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates APR, ZGNX, DNAA, ZNGA, RRD; Shareholders are Encouraged to Contact the Firm
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Jan 26, 2022 10:27 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zogenix, Inc. (Nasdaq - ZGNX), Social Capital Suvretta Holdings Corp. III (Nasdaq - DNAC), Viveon Health Acquis
BALA CYNWYD, Pa., Jan. 26, 2022 /PRNewswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation to you.
Jan 25, 2022 12:18 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ZGNX, BFC, EXTN, SMFR; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Zogenix, Inc. (NASDAQ: ZGNX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jan 22, 2022 02:03 am ET
Lifshitz Law Firm, P.C. Announces Investigation of ATVI, BFC, SMFR, and ZGNX
Activision Blizzard Inc. (NASDAQGS: ATVI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ATVI to Microsoft Corp. for $95.00 in cash per share of ATVI owned. If you are an...
Jan 21, 2022 09:37 am ET
Moore Kuehn Encourages ATVI, ZGNX, DNAC, and VHAQ Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Jan 20, 2022 07:18 pm ET
Investor Alert: The M&A Class Action Firm Announces an Investigation of the Merger - ATVI, DMKBA, ZGNX, EPAY, GCP, MNTV
NEW YORK, Jan. 20, 2022 /PRNewswire/ --Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jan 20, 2022 12:20 am ET
ZOGENIX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zogenix, Inc. - ZGNX
NEW ORLEANS, Jan. 20, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Zogenix, Inc. (NASDAQGM: ZGNX) to UCB. Under the terms of the proposed transaction, shareholders of Zogenix will receive only $26.00 in cash, plus a contingent value right (CVR) for a potential cash payment of $2.00, for each share of Zogenix that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalue
Jan 20, 2022 12:00 am ET
Halper Sadeh LLP Investigates ZGNX, BFC, FLMN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Zogenix, Inc. (NASDAQ: ZGNX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to...
Jan 19, 2022 08:57 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Zogenix, Inc.
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX), in connection with the proposed acquisition of the Company by UCB S.A. ("UCB") (Euronext: UCB) via a tender offer. Under the terms of the acquisition agreement, the Company's shareholders will receive $26.00 in cash, plus a contingent value right for a potential cash payment of $2.00, for each share of Zogenix common stock that they hold. The transaction is valued at approx
Jan 19, 2022 03:44 pm ET
ZOGENIX ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ZGNX and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zogenix, Inc. (NASDAQ: ZGNX) breached their fiduciary duties or violated the federal...
Jan 19, 2022 03:14 pm ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Zogenix, Inc. Merger
Rigrodsky Law, P.A. announces that it is investigating Zogenix, Inc. (“Zogenix”) (NASDAQ GM: ZGNX) regarding possible breaches of fiduciary duties and other violations of law related to Zogenix’s agreement to be acquired by UCB SA (OTC: UCBJY)....
Jan 19, 2022 01:30 pm ET
SHAREHOLDER UPDATE: Brodsky & Smith Reminds Investors of the Following Investigations: Zogenix, Inc. (Nasdaq - ZGNX), Social Capital Suvretta Holdings Corp. III (Nasdaq – DNAC), Viveon Health Acquisit
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation to you. Zogenix, Inc....
Jan 19, 2022 01:12 pm ET
Shareholder Alert: Ademi LLP investigates whether Zogenix, Inc. has obtained a Fair Price in its transaction with UCB.
MILWAUKEE, Jan. 19, 2022 /PRNewswire/ -- Ademi LLP is investigating Zogenix (NASDAQ: ZGNX) for possible breaches of fiduciary duty and other violations of law in its transaction with UCB. 
Jan 19, 2022 12:15 pm ET
Zogenix (ZGNX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Zogenix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ZGNX
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would acquire Zogenix for $26.00 per share in cash, plus a contingent value right for a potential cash payment of $2.00 per share upon EU approval by December 31, 2023, of FINTEPLA®.
Jan 19, 2022 10:31 am ET
ZGNX Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Acquisition of Zogenix by UCB
The law firm of Wohl & Fruchter LLP is investigating whether the directors of Zogenix, Inc. (Nasdaq: ZGNX) (“Zogenix”) acted in the best interests of ZGNX shareholders in approving the proposed acquisition of Zogenix by UCB, a global...
Jan 19, 2022 07:35 am ET
Thinking about buying stock in Zogenix, KE Holdings, SoFi Technologies, Leap Therapeutics, or ADMA Biologics?
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZGNX, BEKE, SOFI, LPTX, and ADMA.
Jan 19, 2022 12:00 am ET
UCB to acquire Zogenix
BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of US$ 26.00 in cash at closing, plus a contingent value right (CVR) for a potentia
Dec 21, 2021 08:00 am ET
Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome
Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA®...
Dec 20, 2021 08:00 am ET
Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it has submitted its Type II Variation Market Authorization Application to the European Medicines Agency (EMA)...
Dec 16, 2021 04:05 pm ET
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to nine (9) new non-executive employees. The awards were made on December 15, 2021, under Zogenix’s 2021 Employment...
Dec 02, 2021 04:16 pm ET
Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will present new FINTEPLA® (fenfluramine) data from eight abstracts at the American Epilepsy Society (AES)...
Dec 01, 2021 08:00 am ET
Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies today announced the U.S. Food and Drug Administration (FDA) has accepted for filing and granted Priority Review to the company’s supplemental New Drug...
Nov 17, 2021 04:05 pm ET
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to thirteen (13) new non-executive employees. The awards were made on November 15, 2021, under Zogenix’s 2021...
Nov 11, 2021 04:05 pm ET
Zogenix to Participate in Two Upcoming Investor Conferences
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual...
Nov 04, 2021 04:05 pm ET
Zogenix Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2021, and provided a corporate update. The Company will host a...
Nov 01, 2021 08:00 am ET
Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase 2 Deficiency and MT-1621
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at...
Oct 21, 2021 08:00 am ET
Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call...
Oct 19, 2021 08:00 am ET
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to thirty-four (34) new non-executive employees. The awards were made on October 15, 2021, under Zogenix’s 2021...
Sep 30, 2021 08:00 am ET
New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)
Median reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p90% of patient data were available. The median baseline drop seizure frequency prior to study treatment was 75 per month (range 4 - 2943). Results presented as of the...
Sep 28, 2021 08:00 am ET
Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) for FINTEPLA® (fenfluramine) for the treatment of seizures associated...
Sep 16, 2021 05:39 pm ET
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees. The awards were made on September 15, 2021, under Zogenix’s 2021 Employment...
Aug 26, 2021 08:00 am ET
Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Japanese Ministry of Health, Labour & Welfare (MHLW) has granted Orphan Drug Designation to FINTEPLA® (fenfluramine) oral...
Aug 16, 2021 05:01 pm ET
Zogenix Reports Granting of Inducement Awards
Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen new employees. The awards were made on August 15, 2021, under Zogenix’s 2021 Employment Inducement...
Aug 05, 2021 04:01 pm ET
Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and six months ended June 30, 2021, and provided a corporate update. The Company will...
Aug 03, 2021 04:05 pm ET
Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will...
Jul 22, 2021 08:00 am ET
Zogenix to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter ended June 30, 2021 and host a corporate update...
Jul 21, 2021 08:00 am ET
Zogenix Product FINTEPLA® (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment Outcomes
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that its product FINTEPLA® (fenfluramine) oral solution has been recognized by two distinguished clinicians in an Epilepsy &...
Jul 14, 2021 04:01 pm ET
VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy Groups
Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP Siblings, a new website and suite of materials created to celebrate and deepen support for...
Jun 21, 2021 08:00 am ET
Zogenix to Participate in Two Upcoming Investor Conferences
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming investor conferences: the Raymond James Human...
May 11, 2021 04:01 pm ET
Zogenix to Participate in the BofA Securities 2021 Healthcare Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief...
May 06, 2021 04:01 pm ET
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three months ended March 31, 2021, and provided a corporate update. The Company will host a...
Apr 27, 2021 08:00 am ET
Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine) Oral Solution
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced the launch of its new global access program for FINTEPLA (fenfluramine) oral solution. FINTEPLA was approved in the U.S. and European...
Apr 22, 2021 08:01 am ET
Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new data showing the positive impact of treatment with FINTEPLA® (fenfluramine) oral solution on everyday executive function for children...
Apr 22, 2021 08:00 am ET
Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and host a corporate update conference call and...
Apr 16, 2021 08:00 am ET
Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and...
Apr 08, 2021 08:00 am ET
Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief...
Mar 25, 2021 08:00 am ET
Zogenix to Participate in the Stifel 3rd Annual CNS Day
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief...
Mar 02, 2021 08:00 am ET
Zogenix to Participate in the Raymond James Institutional Investors Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corporate...
Feb 25, 2021 04:01 pm ET
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2020. The...
Feb 18, 2021 08:00 am ET
Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10th Annual SVB Leerink Global...
Feb 11, 2021 08:00 am ET
Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate update...
Feb 01, 2021 03:00 am ET
Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA® (fenfluramine) oral solution is now available in Germany for the treatment of seizures associated with Dravet syndrome in...
Jan 11, 2021 08:00 am ET
Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported select preliminary, unaudited financial results for the fourth quarter and full-year 2020. In addition, the Company...
Dec 21, 2020 08:00 am ET
The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA® (fenfluramine) oral solution for the treatment of...
Dec 03, 2020 04:42 pm ET
Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies
CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies.
Dec 01, 2020 08:00 am ET
Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that data from eleven poster presentations related to FINTEPLA® (fenfluramine) oral solution in Dravet syndrome,...
Nov 11, 2020 08:00 am ET
Zogenix to Participate in the Stifel 2020 Virtual Healthcare Conference
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, and...
Nov 09, 2020 04:01 pm ET
Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2020 and provided a corporate update. The Company...
Oct 29, 2020 08:00 am ET
Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast to November 9
Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed the date of its previously announced earnings release and earnings call. The Company will now report its...
Oct 26, 2020 08:00 am ET
Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10
Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update...
Oct 16, 2020 08:00 am ET
Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome
Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), has adopted a positive...
Oct 15, 2020 04:16 pm ET
Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, shared new data analyses for FINTEPLA® (fenfluramine) oral solution in Dravet syndrome at the Child Neurology Society and International Child...
Oct 05, 2020 04:03 pm ET
Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $30.0 Million of 2.75% Convertible Senior Notes Due 2027
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the initial purchasers of the previously announced offering of its 2.75% convertible senior notes due 2027 in a private...
Oct 02, 2020 08:00 am ET
Zogenix Presents New Data at the World Muscle Society Conference 2020
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigational therapy for...
Sep 23, 2020 10:59 pm ET
Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering
Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule...
Sep 22, 2020 04:13 pm ET
Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering
Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional...
Sep 21, 2020 08:04 pm ET
CORRECTING and REPLACING - Zogenix Appoints Three Industry Leaders to Its Board of Directors
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board of...
Sep 21, 2020 08:00 am ET
Zogenix Appoints Three Industry Leaders to Its Board of Directors
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board of...
Sep 10, 2020 08:00 am ET
Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial (Study 3) of FINTEPLA® in Dravet Syndrome
Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported positive top-line results from its third Phase 3 study (Study 3) of FINTEPLA® (fenfluramine) oral solution for the...
Aug 05, 2020 04:01 pm ET
Zogenix Provides Corporate Update and Reports Second Quarter 2020 Financial Results
Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and six months ended June 30, 2020, and provided a corporate update. The...
Jul 29, 2020 08:00 am ET
Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a...
Jun 25, 2020 11:05 pm ET
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
EMERYVILLE, Calif., June 25, 2020 /PRNewswire/ -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA® (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA will be launched through a restricted distribution program, called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) Program, and is expected to be available through Zogenix's specialty pharmacy partner by the
Jun 25, 2020 08:49 pm ET
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA® (fenfluramine) oral solution, CIV for the treatment of seizures...
Jun 12, 2020 08:00 am ET
Zogenix Introduces New Resources for Dravet Syndrome Siblings
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the introduction in the U.S. of a new suite of materials to better support and celebrate siblings of those living with Dravet syndrome....
May 06, 2020 08:00 am ET
Zogenix to Participate in the BofA Securities 2020 Virtual Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Wednesday, May 13, 2020, at the BofA Securities 2020 Virtual...
May 05, 2020 04:01 pm ET
Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three months ended March 31, 2020, and provided a corporate update. The Company will host a conference call...
Apr 28, 2020 08:00 am ET
Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close, and will host a corporate...
Apr 20, 2020 08:00 am ET
Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has appointed Shawnte M. Mitchell to the role of Executive Vice President, General Counsel and Secretary. In this role, Ms. Mitchell...
Apr 15, 2020 08:00 am ET
Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor conference call and webcast on two studies evaluating its investigational drug, FINTEPLA®, in Dravet...
Mar 06, 2020 04:05 pm ET
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its previously announced underwritten public offering of 9,798,000 shares of its common stock, including 1,278,000...
Mar 03, 2020 09:05 pm ET
Zogenix Prices Public Offering of Common Stock
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per...
Mar 03, 2020 05:07 pm ET
Zogenix Announces Proposed Public Offering of Common Stock
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public...
Mar 02, 2020 04:01 pm ET
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today provided a corporate update and announced financial results for the quarter and full-year ended December 31, 2019. The Company will host a...
Feb 27, 2020 08:00 am ET
Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for FINTEPLA® for...
Feb 24, 2020 08:00 am ET
Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2019, after the market close, and...
Feb 06, 2020 04:01 pm ET
Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008,...
Dec 17, 2019 07:04 pm ET
The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that The Lancet has published the results of its Phase 3 clinical trial, Study 1, of the Company’s investigational drug, FINTEPLA®...
Dec 05, 2019 08:15 am ET
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution), on Monday,...
Dec 02, 2019 04:01 pm ET
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that JAMA Neurology has published the results of Zogenix’s Phase 3 study (Study 1504) of the investigational drug, FINTEPLA® (ZX008,...
Dec 02, 2019 08:00 am ET
Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution), for the treatment of...
Nov 27, 2019 08:00 am ET
Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Thursday, December 5, 2019, at the 31st Annual Piper Jaffray...
Nov 25, 2019 08:00 am ET
Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for FINTEPLA® (ZX008,...
Nov 21, 2019 02:42 pm ET
Shareholder Alert: Robbins LLP Reminds Investors Zogenix, Inc. (ZGNX) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Zogenix, Inc. (NASDAQ: ZGNX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 6, 2019 and April 8, 2019. Zogenix is a pharmaceutical company that develops and commercializes therapies for the treatment of transfor
Nov 12, 2019 08:00 am ET
Zogenix to Present at Two Investor Conferences in November
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will...
Nov 07, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2019, and provided a corporate update. The Company will host a...
Oct 31, 2019 08:00 am ET
Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2019, after the market close, and will host...
Oct 25, 2019 09:00 am ET
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced positive new data for its investigational drug, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Dravet...
Oct 21, 2019 08:00 am ET
Zogenix Announces Presentation of New Data for FINTEPLA® for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that five posters related to its investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution), will be presented at the 48th Annual...
Oct 08, 2019 08:28 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of CBL & Associates Properties, EQT Corporation, and Zogenix and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of CBL & Associates Properties, Inc. (NYSE: CBL), EQT Corporation (NYSE: EQT), and Zogenix, Inc. (NASDAQ: ZGNX) on behalf of long-term stockholders.  More information about each...
Oct 07, 2019 08:00 am ET
Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, and its wholly-owned subsidiary, Modis Therapeutics,  presented positive top-line results from its pivotal Phase 2 RETRO study at the recent World...
Sep 26, 2019 07:00 am ET
Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine) for the treatment of seizures associated...
Sep 23, 2019 05:23 pm ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of the securities laws. The...
Sep 18, 2019 08:49 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Orion Group Holdings, Zogenix, and Apyx and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of Orion Group Holdings, Inc. (NYSE: ORN), Zogenix, Inc. (NASDAQ: ZGNX), and Apyx Medical Corporation (NASDAQ: APYX) on behalf of long-term stockholders. More information about...
Sep 16, 2019 05:10 pm ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities...
Sep 09, 2019 08:00 am ET
Zogenix Completes Acquisition of Modis Therapeutics, Inc.
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition of Modis Therapeutics, Inc., a privately-held biopharmaceutical company, and added...
Sep 04, 2019 09:04 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities...
Sep 03, 2019 02:49 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Aug 29, 2019 10:19 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Aug 26, 2019 07:00 am ET
Zogenix Announces Acquisition of Modis Therapeutics, Inc.
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into a definitive agreement to acquire Modis Therapeutics, Inc., a privately held biopharmaceutical company...
Aug 06, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three and six months ended June 30, 2019, and provided a corporate update. The Company will host a conference...
Jul 30, 2019 08:00 am ET
Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2019, after the market close, and will host a...
Jul 08, 2019 08:00 am ET
Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company’s Phase 3...
Jun 27, 2019 08:00 am ET
Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final minutes from the U.S. Food and Drug Administration (FDA) from the Type A meeting held on May 30, 2019,...
Jun 11, 2019 02:42 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) investors who purchased...
Jun 07, 2019 03:00 pm ET
Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) & Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 07, 2019 11:06 am ET
ZGNX ALERT:  Zhang Investor Law Reminds Investors of June 11 Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover...
Jun 06, 2019 08:11 pm ET
ZGNX and APYX DEADLINE ALERT: Hagens Berman Reminds APYX and ZGNX Investors of Lead Plaintiff Deadlines
Hagens Berman Sobol Shapiro LLP reminds investors in ZGNX and APYX of immediately approaching lead plaintiff deadlines in pending securities class actions. Zogenix, Inc. (NASDAQ: ZGNX)CLASS PERIOD: Feb. 6, 2019 - April 8, 2019LEAD PLAINTIFF...
Jun 06, 2019 09:50 am ET
CLASS ACTION UPDATE for ZGNX, MWA, KSHB and SCOR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jun 05, 2019 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
Jun 05, 2019 07:01 pm ET
ZGNX NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Investigation of Securities Claims Against Zogenix, Inc. Investors with Losses in Excess of $100K are Encouraged to Contact the Firm – ZGN
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Zogenix, Inc. (NASDAQ: ZGNX) resulting from allegations that Zogenix may have issued materially misleading business information to the investing public.
Jun 05, 2019 06:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors. The class action, filed in United States District Court, United District...
Jun 04, 2019 03:47 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc.  (“Zogenix” or the “Company”) (NASDAQ: ZGNX) investors who purchased...
Jun 04, 2019 09:56 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
Jun 04, 2019 09:19 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZGNX, INVVY, JMIA and XENT
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 03, 2019 03:01 pm ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
May 31, 2019 08:09 pm ET
CLASS ACTION UPDATES for BA, CRCM, ZGNX, INVVY: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders
Hagens Berman Sobol Shapiro LLP reminds BA, CRCM, ZGNX, INVVY investors that class action lawsuits have commenced on behalf of investors in the following companies and lead plaintiff filing deadlines are approaching. The Boeing Company (NYSE:...
May 31, 2019 03:00 pm ET
Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) &  Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Announces Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 31, 2019 02:27 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Zogenix, Inc. Investors of Important June 11th Deadline in Securities Class Action – ZGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”) of the important June 11, 2019 lead plaintiff...
May 31, 2019 09:55 am ET
CLASS ACTION UPDATE for EB, FSNN, ZGNX and XENT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 30, 2019 09:15 am ET
CLASS ACTION UPDATE for WSR, ZGNX, LYFT and XENT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 29, 2019 10:10 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 27, 2019 10:30 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
May 26, 2019 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline– ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.  The class action, filed in United States District Court, United...
May 23, 2019 08:09 pm ET
ZGNX CLASS ACTION REMINDER: Hagens Berman Reminds Zogenix (ZGNX) Investors of Class Action of Upcoming Deadline
Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, reminds investors in Zogenix, Inc. (NASDAQ: ZGNX) of the upcoming June 11, 2019 lead plaintiff movant deadline in the securities class...
May 23, 2019 11:36 am ET
ZGNX JUNE 11th DEADLINE: Rosen Law Firm Reminds Zogenix, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses over $100K to Contact the Firm – ZGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”) of the important June 11, 2019 lead plaintiff...
May 22, 2019 11:12 am ET
ZGNX DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
May 22, 2019 10:40 am ET
CLASS ACTION UPDATE for CRCM, ZGNX, S and EQBK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 22, 2019 05:20 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc. Stockholders have until the...
May 21, 2019 04:38 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 20, 2019 03:25 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
May 20, 2019 03:00 pm ET
SHAREHOLDER ALERT - Zogenix, Inc. (ZGNX) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: June 11, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers, on behalf of shareholders who...
May 20, 2019 10:40 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
May 17, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 15, 2019 12:50 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 15, 2019 09:47 am ET
CLASS ACTION UPDATE for T, HCSG, NTNX and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 14, 2019 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline- ZGNX
NEW YORK, May 14, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX) and certain of its officers and directors.  The class action, filed in United States District Court, United District Court, Northern District of California, and indexed under 19-cv-01975, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired Zogenix's securities between February 6, 2019 through April 8, 2019, both dates inclusive (the "Class
May 14, 2019 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline- ZGNX
NEW YORK, May 14, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX) and certain of its officers and directors.  The class action, filed in United States District Court, United District Court, Northern District of California, and indexed under 19-cv-01975, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired Zogenix's securities between February 6, 2019 through April 8, 2019, both dates inclusive (the
May 13, 2019 04:40 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 13, 2019 04:20 pm ET
SHAREHOLDER ALERT: MBT NTNX ZGNX INVVY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
May 13, 2019 02:45 pm ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
May 12, 2019 09:29 am ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses to Contact the Firm
SAN DIEGO, May 12, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased a common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as
May 10, 2019 05:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 09, 2019 03:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors. The class action, filed in United States District Court, United District...
May 08, 2019 05:10 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of SCOR, MWA, and ZGNX of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: comScore, Inc. (NASDAQ GS: SCOR) Class Period: November 8, 2018 - March 29, 2019Lead...
May 08, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three months ended March 31, 2019 and provided a corporate update. The Company will host a conference call...
May 07, 2019 01:54 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 07, 2019 10:10 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZVO, CNDT, ZGNX and S
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
May 07, 2019 08:00 am ET
Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will...
May 03, 2019 05:49 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of SCOR, MWA, and ZGNX of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: comScore, Inc. (NASDAQ GS: SCOR) Class Period: November 8, 2018 - March 29, 2019Lead...
May 03, 2019 03:52 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: 
May 03, 2019 10:30 am ET
CLASS ACTION UPDATE for CORT, WTW, CTL and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 03, 2019 09:39 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 02, 2019 05:48 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) securities between February 6, 2019 and April 8, 2019, inclusive
May 02, 2019 05:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
May 02, 2019 04:29 pm ET
ZGNX CLASS ACTION ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc. - ZGNX
NEW YORK, May 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws.
May 01, 2019 08:03 pm ET
ZGNX CLASS ACTION REMINDER: Hagens Berman Reminds Zogenix (ZGNX) Investors of Securities Class Action, Encourages Investors Who Suffered Losses of $50,000+ to Contact the Firm
Hagens Berman Sobol Shapiro LLP, with 9 offices in 8 cities around the country and 80 attorneys, reminds investors in Zogenix, Inc. (NASDAQ: ZGNX) of the securities class action pending in the United States District Court for the Northern District...
May 01, 2019 04:47 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement awards to nine new non-executive employees.  The awards were made on May 1, 2019 under Zogenix’s...
May 01, 2019 03:44 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 01, 2019 08:00 am ET
Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three months ended March 31, 2019, after the market close, and will host a corporate...
Apr 30, 2019 05:19 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Zogenix, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 29, 2019 03:30 pm ET
ZGNX DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
Apr 28, 2019 09:00 am ET
INVESTOR ALERT: Kaskela Law LLC Announces Important Shareholder Class Action Lawsuit Deadlines – BA, SCOR, MWA and ZGNX
Kaskela Law LLC announces that shareholder class action lawsuits have been filed against The Boeing Company (NYSE: BA), comScore, Inc. (Nasdaq: SCOR), Mueller Water Products, Inc. (NYSE: MWA) and Zogenix, Inc. (Nasdaq: ZGNX).  Additional...
Apr 26, 2019 03:54 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Corporation Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ:
Apr 26, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
Apr 25, 2019 05:57 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Investors (ZGNX)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) securities between February 6, 2019 and April 8, 2019, inclusive (the “Class Period”). Zogenix investors have until June 11, 2019 t
Apr 25, 2019 05:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
Apr 22, 2019 04:47 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
NEW YORK, April 22, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 19, 2019 03:53 pm ET
ZGNX CLASS ACTION ALERT: Rosen Law Firm Reminds Zogenix, Inc. Investors of Important Deadline in Securities Class Action – ZGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”) of the important June 11, 2019 lead plaintiff deadline in class action. The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws.
Apr 19, 2019 10:47 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of EB, BV, ZGNX and MWA
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Apr 18, 2019 08:48 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Apr 18, 2019 07:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (Nasdaq: ZGNX) in the United States District Court for the Northern District of California on behalf of those who...
Apr 18, 2019 03:18 pm ET
Pawar Law Group Announces a Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
Apr 18, 2019 02:51 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline– ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
Apr 18, 2019 12:21 pm ET
Robbins Arroyo LLP: Zogenix, Inc. (ZGNX) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Zogenix, Inc. filed a class action complaint against Zogenix, Inc. (NASDAQ: ZGNX) for alleged violations of the Securities Exchange Act of 1934 between February 6, 2019 and April 8, 2019. Zogenix is a pharmaceutical company that de
Apr 18, 2019 10:11 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KHC, ZGNX, BA and MWA
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 17, 2019 09:02 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zogenix, Inc. investors (“Zogenix” or the “Company”) (NASDAQ: ZGNX) concerning the Company and its officers’ possible violations of federal securities laws. If you are a...
Apr 17, 2019 04:50 pm ET
ZOGENIX, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of the securities of Zogenix, Inc....
Apr 17, 2019 12:51 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zogenix, Inc.
Rigrodsky & Long, P.A.: Do you, or did you, own shares of Zogenix, Inc. (NASDAQ GM: ZGNX)? Did you purchase your shares between February 6, 2019 and April 8, 2019, inclusive? Did you lose money in your investment? Rigrodsky & Long, P.A. announces...
Apr 17, 2019 09:41 am ET
SHAREHOLDER ALERT: DPLO BV ZGNX MWA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.